spacer
home > pmps > spring 2017 > partial to particles
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Partial to Particles

Dry powder inhalers (DPIs) are almost exclusively passive devices, relying on the energy supplied by the inhaling patient for dose dispersion. Consequently, their designs are crucial in determining the extent to which this limited energy supply aerosolises the formulation to a respirable particle size. With growing focus on particles towards the finer end of the size distribution, achieving consistent and effective dispersion with any given inhalation profile is becoming increasingly important.

The incorporation of a breath-actuated mechanism (BAM) has been shown to enhance the dispersion performance of DPIs. It works by inhibiting the release of the dose until the pressure drop across the device reaches a certain value, thereby promoting highly energetic dispersion and efficient delivery.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr David Lewis is Head of Laboratory at Chiesi’s Research Centre in Chippenham, UK, which he established in July 2009. He holds a BSc in Physics as well as an MSc and PhD in Aerosol Science from the University of Essex, UK. David has authored over 130 research publications within the fields of pharmaceutics, analytical chemistry and aerosol science, and is co-inventor of 30 patents relating to pressurised MDI formulations and devices.

After graduating from the University of Southampton, UK, Alan Tweedie worked for a year as a Quality Control Chemist at a UK biotechnology company. He then moved to Bristol, where he joined Vectura, a pharma firm specialising in inhalation therapy. As part of an early-stage feasibility team, Alan was involved in the manufacture and analysis of dry powder formulations, discovering a particular interest in the interactions that exist between the device and formulation. In 2011, he started working for Chiesi at the Chippenham Research Centre.

Francesca Mason graduated from the University of Bradford, UK, in 2010 with a degree in Chemistry, Pharmaceuticals and Forensic Science. She joined Chiesi in 2011 at the Chippenham Research Centre and has now been a Scientist for more than five years. Francesca has predominately worked within the atomisation team involved in creating novel and innovative formulation and technology platforms for inhaled drug delivery.
spacer
Dr David Lewis
spacer
spacer
spacer
Alan Tweedle
spacer
spacer
spacer
Francesca Mason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

 
Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement